arrow_back Back to App

Prescription Drug Price Relief Act: Ending High-Cost Monopolies

This act aims to lower prescription drug prices in the U.S. It establishes a process to identify drugs with prices higher than in other countries, then allows for the production of cheaper alternatives. This could lead to lower healthcare costs and improved access to essential medications for citizens.
Key points
The government will compare U.S. drug prices with those in Canada, UK, Germany, France, and Japan to identify overpriced drugs.
If a drug is deemed excessively priced, the government can allow other companies to produce cheaper versions, increasing competition.
Drug manufacturers must regularly report pricing and cost data, facing penalties for non-compliance.
A public database will be created, allowing anyone to see which drugs are overpriced and for which cheaper alternatives are available.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_S_909
Sponsor: Sen. Sanders, Bernard [I-VT]
Process start date: 2021-03-23
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Prescription Drug Price Relief Act of 2021

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_S_909.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2021-03-23.

What are the main provisions?

Key points include:

  • The government will compare U.S. drug prices with those in Canada, UK, Germany, France, and Japan to identify overpriced drugs.
  • If a drug is deemed excessively priced, the government can allow other companies to produce cheaper versions, increasing competition.
  • Drug manufacturers must regularly report pricing and cost data, facing penalties for non-compliance.
  • A public database will be created, allowing anyone to see which drugs are overpriced and for which cheaper alternatives are available.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Sanders, Bernard [I-VT].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-29.

CATEGORIES

Health Economy